Hong Julian C, Foote Jonathan, Broadwater Gloria, Sosa Julie A, Gaillard Stephanie, Havrilesky Laura J, Chino Junzo P
All authors: Duke University Medical Center, Durham, NC.
JCO Clin Cancer Inform. 2017 Nov;1:1-15. doi: 10.1200/CCI.16.00072.
Prior studies have demonstrated the importance of treatment duration (TD) in radiation therapy (RT) for cervical cancer, with an 8-week goal based primarily on RT alone. This study uses a contemporary cohort to estimate the time point by which completion of chemoradiation therapy is most critical.
The National Cancer Database was queried for women with nonmetastatic cervical cancer diagnosed from 2004 to 2012 who underwent chemotherapy, external beam RT, and brachytherapy. Data-derived TD cut points for overall survival (OS) were computed by using recursive partitioning analysis with bootstrapped aggregation (bagging) and 10-fold cross-validation. Models were independently trained with 70% of the population and validated on 30% of the population by log-rank test with and without propensity matching. Multivariable Cox proportional hazards regression was performed for the entire cohort.
In all, 7,355 women were identified with a median TD of 57 days. Bagged recursive partitioning analysis converged to a mean cut point of 66.6 days (median, 64.5 days; interquartile range, 63.5 to 68.5 days). Cross-validation yielded a cut point of 63.3 days. Both cut points differentiated OS in validation. Younger age, recent diagnosis, geographic region, nongovernment insurance, shorter distance to treatment facility, metropolitan location, lower comorbidity, squamous cell carcinoma, lower stage, negative lymph nodes, and shorter TD were independently associated with longer OS. With adjustment, TD within the mean cut point (64.9 days; hazard ratio, 0.79; 95% CI, 0.73 to 0.87) and 56 days (hazard ratio, 0.87; 95% CI, 0.80 to 0.95) were associated with longer OS. Exploratory stratification suggested increasing OS detriment beyond 64 days.
Shorter chemoradiation TD in cervical cancer is associated with longer survival, and TD should be minimized as much as possible. The data-derived cut point was distributed around 64 days, with a continuous relationship between shorter TD and longer OS.
先前的研究已证明治疗持续时间(TD)在宫颈癌放射治疗(RT)中的重要性,主要基于单纯放疗设定了8周的目标。本研究使用当代队列来估计完成放化疗最为关键的时间点。
查询国家癌症数据库,纳入2004年至2012年诊断为非转移性宫颈癌且接受化疗、外照射放疗和近距离放疗的女性。通过使用带有自助聚合(装袋法)和10倍交叉验证的递归划分分析,计算得出总生存(OS)的数据衍生TD切点。模型使用70%的人群进行独立训练,并通过对数秩检验在30%的人群上进行验证,有无倾向匹配。对整个队列进行多变量Cox比例风险回归分析。
总共识别出7355名女性,TD中位数为57天。装袋递归划分分析收敛到平均切点为66.6天(中位数为64.5天;四分位间距为63.5至68.5天)。交叉验证得出切点为63.3天。两个切点在验证中均能区分OS。年龄较小、近期诊断、地理区域、非政府保险、到治疗机构的距离较短、大都市地区、合并症较低、鳞状细胞癌、分期较低、淋巴结阴性以及TD较短与较长的OS独立相关。经过调整,处于平均切点(64.9天;风险比为0.79;95%可信区间为0.73至0.87)和56天(风险比为0.87;95%可信区间为0.80至0.95)内的TD与较长的OS相关。探索性分层表明,超过64天时OS损害增加。
宫颈癌较短的放化疗TD与较长的生存期相关,应尽可能将TD减至最短。数据衍生切点分布在64天左右,TD越短与OS越长之间存在连续关系。